BR112014016557A8 - métodos de tratamento de sintomas comportamentais de distúrbios neurológicos e mentais - Google Patents

métodos de tratamento de sintomas comportamentais de distúrbios neurológicos e mentais

Info

Publication number
BR112014016557A8
BR112014016557A8 BR112014016557A BR112014016557A BR112014016557A8 BR 112014016557 A8 BR112014016557 A8 BR 112014016557A8 BR 112014016557 A BR112014016557 A BR 112014016557A BR 112014016557 A BR112014016557 A BR 112014016557A BR 112014016557 A8 BR112014016557 A8 BR 112014016557A8
Authority
BR
Brazil
Prior art keywords
methods
disorders
neurological
treating
disclosed
Prior art date
Application number
BR112014016557A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112014016557A2 (pt
Inventor
J Fallon James
Szigethy James
M Fallon Joan
Nanus Kenneth
F Heil Matthew
Original Assignee
Curemark Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curemark Llc filed Critical Curemark Llc
Publication of BR112014016557A2 publication Critical patent/BR112014016557A2/pt
Publication of BR112014016557A8 publication Critical patent/BR112014016557A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Closures For Containers (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
BR112014016557A 2012-01-03 2013-01-03 métodos de tratamento de sintomas comportamentais de distúrbios neurológicos e mentais BR112014016557A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261582813P 2012-01-03 2012-01-03
US201261600110P 2012-02-17 2012-02-17
PCT/US2013/020183 WO2013103746A1 (en) 2012-01-03 2013-01-03 Methods of treating behavioral symptoms of neurological and mental disorders

Publications (2)

Publication Number Publication Date
BR112014016557A2 BR112014016557A2 (pt) 2017-06-13
BR112014016557A8 true BR112014016557A8 (pt) 2017-07-04

Family

ID=48745413

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014016557A BR112014016557A8 (pt) 2012-01-03 2013-01-03 métodos de tratamento de sintomas comportamentais de distúrbios neurológicos e mentais

Country Status (16)

Country Link
US (3) US20130224172A1 (enExample)
EP (1) EP2800581B1 (enExample)
JP (3) JP6796372B2 (enExample)
KR (3) KR20190109564A (enExample)
CN (2) CN104144698A (enExample)
AU (2) AU2013206890B2 (enExample)
BR (1) BR112014016557A8 (enExample)
CA (1) CA2862403C (enExample)
DK (1) DK2800581T3 (enExample)
GB (1) GB2511713B (enExample)
HK (1) HK1257360A1 (enExample)
IL (1) IL233372B (enExample)
MX (2) MX363096B (enExample)
NZ (2) NZ737957A (enExample)
RU (1) RU2654230C2 (enExample)
WO (1) WO2013103746A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070053895A1 (en) 2000-08-14 2007-03-08 Fallon Joan M Method of treating and diagnosing parkinsons disease and related dysautonomic disorders
US8030002B2 (en) 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
US9320780B2 (en) 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
PL2318035T3 (pl) 2008-07-01 2019-10-31 Curemark Llc Sposoby i kompozycje do leczenia objawów zaburzeń neurologicznych i zaburzeń zdrowia psychicznego
US10776453B2 (en) 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
US20100092447A1 (en) 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
CA2747703C (en) 2009-01-06 2021-06-15 Curemark Llc Compositions and methods for the treatment or the prevention of infections by e. coli
JP5684725B2 (ja) 2009-01-06 2015-03-18 キュレロン リミテッド ライアビリティ カンパニー 黄色ブドウ球菌感染の治療または予防のための組成物および方法ならびに表面上にいる黄色ブドウ球菌の根絶または低減のための組成物および方法
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
US9511125B2 (en) 2009-10-21 2016-12-06 Curemark Llc Methods and compositions for the treatment of influenza
DK2701733T3 (da) 2011-04-21 2019-05-27 Curemark Llc Forbindelser til behandling af neuropsykiatriske forstyrrelser
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
US10813901B2 (en) 2013-10-22 2020-10-27 Yamo Pharmaceuticals Llc Compositions and methods for treating autism
AU2016247301A1 (en) * 2015-04-14 2017-10-26 Steven Hoffman Compositions and methods for treating autism
CN105213433A (zh) * 2015-11-06 2016-01-06 王益超 一种用于治疗孤独症、复发性流产和不孕症的组合物
WO2018191233A1 (en) 2017-04-10 2018-10-18 Curemark, Llc Compositions for treating addiction
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
US11547707B2 (en) * 2019-04-10 2023-01-10 Richter Gedeon Nyrt. Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
US20210043106A1 (en) * 2019-08-08 2021-02-11 COGNITIVEBOTICS Technologies Pvt. Ltd. Technology based learning platform for persons having autism
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
CN112347257B (zh) * 2020-11-11 2024-07-09 北京嘉和海森健康科技有限公司 一种患者症状口语化标准化方法和装置
WO2023201358A2 (en) * 2022-04-15 2023-10-19 AEON Biopharma, Inc. Neurotoxin compositions for use in regulating brain temperature

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1509866A (en) * 1975-06-10 1978-05-04 Johnson & Johnson Enteric coated digestive enzyme compositions
US6632429B1 (en) * 1999-12-17 2003-10-14 Joan M. Fallon Methods for treating pervasive development disorders
US6534063B1 (en) * 1999-12-17 2003-03-18 Joan M. Fallon Methods for treating pervasive development disorders
US6251478B1 (en) 1999-12-22 2001-06-26 Balchem Corporation Sensitive substance encapsulation
US6261613B1 (en) 2000-02-15 2001-07-17 General Mills, Inc. Refrigerated and shelf-stable bakery dough products
US6399114B2 (en) * 2000-05-26 2002-06-04 C & D Foreman, Inc. Nutritional system for nervous system disorders
US6660831B2 (en) 2000-08-14 2003-12-09 Joan M. Fallon Method for diagnosing and treating dysautonomia and other dysautonomic conditions
DE10065123B4 (de) * 2000-12-28 2012-12-20 Robert Bosch Gmbh Verfahren zur Steuerung einer Diagnose eines Katalysators im Abgas eines Verbrennungsmotors
AU2002364750A1 (en) * 2001-12-14 2003-06-30 Solvay Pharmaceuticals Gmbh Use of digestive enzyme mixtures for treating pathological bacterial overgrowth of the small intestine of mammals and humans
CA2560613C (en) * 2004-03-22 2015-11-24 Solvay Pharmaceuticals Gmbh Oral pharmaceutical compositions of lipase-containing products, in particular of pancreatin, containing surfactants
US20060115467A1 (en) * 2004-12-01 2006-06-01 Pangborn Jon B Compositions and methods for the treatment of autism
PL2318035T3 (pl) 2008-07-01 2019-10-31 Curemark Llc Sposoby i kompozycje do leczenia objawów zaburzeń neurologicznych i zaburzeń zdrowia psychicznego
US9056050B2 (en) * 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
JP5914357B2 (ja) * 2010-01-15 2016-05-11 インセルム（インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル） 自閉症の治療のための化合物

Also Published As

Publication number Publication date
GB201411821D0 (en) 2014-08-13
NZ734194A (en) 2021-02-26
AU2017232048A1 (en) 2017-10-12
MX2019002669A (es) 2019-05-30
GB2511713A (en) 2014-09-10
AU2017232048B2 (en) 2019-05-02
IL233372B (en) 2019-09-26
MX363096B (es) 2019-03-08
IL233372A0 (en) 2014-08-31
MX2014008156A (es) 2015-04-13
HK1257360A1 (zh) 2019-10-18
US20210162024A1 (en) 2021-06-03
RU2654230C2 (ru) 2018-05-17
JP2015503586A (ja) 2015-02-02
KR20200113029A (ko) 2020-10-05
EP2800581A4 (en) 2015-08-12
WO2013103746A1 (en) 2013-07-11
NZ716627A (en) 2017-08-25
US20130224172A1 (en) 2013-08-29
HK1201731A1 (en) 2015-09-11
EP2800581B1 (en) 2024-05-22
CN104144698A (zh) 2014-11-12
NZ737957A (en) 2021-07-30
RU2014130165A (ru) 2016-02-27
JP6810724B2 (ja) 2021-01-06
US20260069667A1 (en) 2026-03-12
DK2800581T3 (da) 2024-06-17
CA2862403C (en) 2022-08-09
JP2019006788A (ja) 2019-01-17
EP2800581A1 (en) 2014-11-12
CA2862403A1 (en) 2013-07-11
JP2021001222A (ja) 2021-01-07
KR20140107665A (ko) 2014-09-04
AU2013206890A1 (en) 2014-07-24
BR112014016557A2 (pt) 2017-06-13
JP6796372B2 (ja) 2020-12-09
KR102315761B1 (ko) 2021-10-20
AU2013206890B2 (en) 2017-09-28
GB2511713B (en) 2020-03-04
KR20190109564A (ko) 2019-09-25
CN108578684A (zh) 2018-09-28

Similar Documents

Publication Publication Date Title
BR112014016557A2 (pt) métodos de tratamento de sintomas comportamentais de distúrbios neurológicos e mentais
GB2480987B (en) Enzyme delivery systems and methods of preparations and use
BR112013026114A2 (pt) composições nutricionais que incluem ácidos graxos de cadeia ramificada e processos de utilização das mesmas
CY1122128T1 (el) Θεραπεια ενζυμικης αντικαταστασης με κλιμακωση δοσης για αντιμετωπιση ανεπαρκειας σε οξινη σφιγγομυελιναση
CY1118934T1 (el) Παρασκευη ενεργης ακρως φωσφορυλιωμενης ανθρωπινης ν-ακετυλογαλακτοζαμινης-6-σουλφατασης και χρησεις αυτης
GB2497715A (en) Preparation and use of combination enzyme and gastriontestinal modulator delivery systems
EP4413994A3 (en) Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
AR093181A1 (es) Formulacion con contenido de enzimas digestivas bajo estable
BRPI0810336A2 (pt) "método para tratar e/ou prevenir úlceras de pele em um indivíduo"
BR112012018500A2 (pt) alguns inibidores de quinurenina-3-monooxigenase, composições farmacêuticas e métodos de uso destas
EA201790267A1 (ru) Новые модуляторы киназ
MX2012014521A (es) Uso de levocetirizina y montelukast en el tratamiento de influenza, resfriado comun e inflamacion.
WO2014004993A3 (en) Methods of reducing ldl-p
BR112014024358A8 (pt) administração subcutânea de iduronato-2-sulfatase
WO2008148573A3 (de) Arzeimittel mit einer wirkstoffkombination enthaltend pantothensäure oder deren derivate zur behandlung von allergischen symptomen
BR112016000658A2 (pt) pancreatina de alta atividade, processo para a preparação de pancreatina de aa tendo atividade lipásica específica de pelo menos aproximadamente 120 usp iu/mg e método de tratamento de um paciente sujeito a uma condição patológica associada com a insuficiência enzimática pandreática
WO2007134118A3 (en) Protein based composition and methods of using same
WO2007132292A3 (en) Therapy for alzheimer's disease
BR112013024909A2 (pt) composto, composição farmacêutica, método para o tratamento, prevenção ou melhoria de um ou mais sintomas de desordem, doença, ou condição mediada por pi3k, e método para modular a atividade enzimática de pi3k
WO2007056301A3 (en) Antibody therapy for treatment of diseases associated with gluten intolerance
TW200833347A (en) Method of treating mucin deficiency with an active pharmaceutical and related composition
HK1203359A1 (en) Enzyme compositions and use thereof for wound healing
BR112012033205B8 (pt) Uso de uma composição compreendendo agentes terapêuticos para liberação ao sistema nervoso central

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]